Mirum Pharmaceuticals, a clinical-stage biotech developing therapies for rare liver diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Foster City, CA-based company was founded in 2018 and it plans to list on the Nasdaq under the symbol MIRM. Citi, Evercore ISI and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.